Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HR+/HER2- Advanced Breast Cancer
Interventions: DRUG: Dalpiciclib|DRUG: Chidamide
Sponsor: Beijing 302 Hospital